Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.51 |
| ▸ | THRA | P10827 | 12/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632608 | 1.00 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414741 | 0.95 | THRB (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22633130 | 0.95 | THRB (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28708390 | 0.91 | THRB (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632571 | 0.87 | THRB (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632900 | 0.86 | THRB (0.48) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29414863 | 0.86 | THRB (0.48) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL38660927 | 0.84 | THRB (0.49) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22643873 | 0.82 | THRB (0.61) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22633093 | 0.80 | THRB (0.47) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |